Clinical outcomes associated with glucagon-like peptide-1 receptor agonist therapy in patients with peripheral artery disease and diabetes.
AIM Peripheral artery disease (PAD) and diabetes are associated with high risks of limb complications and mortality. Although glucagon-like peptide-1 receptor agonists (GLP1-RAs) improve cardiovascular outcomes, their effect on limb outcomes in PAD remains uncertain. METHODS We conducted a retrospective cohort study...